← All trials
NCT06178523
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2024
- Primary completion
- Sep 3, 2025
- Completion date
- Sep 3, 2025
- First posted
- Dec 21, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 900
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Batterjee Medical CollegeLead sponsor
- Batterjee Medical CollegeReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.